CD5

PHILADELPHIA, July 22, 2024 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics, a clinical-stage cell therapy company, announces a recent publication by investigators at the University of Pennsylvania in the peer-reviewed journal, Science Immunology. The publication details the critical influence of CD5, a key immunomodulatory protein, on engineered T-cell therapies, which is the foundational basis of the company’s proprietary Senza5TM platform. This technology, developed by the University of Pennsylvania and exclusively licensed to Vittoria, leverages the therapeutic potential of CD5 modulation to enhance the efficacy of CAR T-cell therapies and underscores its utility across multiple hematological and solid tumor animal models. “We are incredibly excited about the findings shared in Science Immunology, which support the clinical translation of our Senza5TM platform and exemplify Vittoria’s commitment to pioneering potent and innovative solutions to advance the field of enabled, autologous cell therapies,” said Nicholas Siciliano, Ph.D., Chief Executive Officer of Vittoria Biotherapeutics. “Despite significant advances in cell therapy across various diseases, considerable unmet needs remain for certain cancers and chronic diseases. This publication comes at a pivotal time as we initiate the clinical trial for our lead program, VIPER-101 for the treatment of T-cell lymphoma.” The research was conducted in the laboratory of Marco Ruella, M.D., a Physician-Scientist in the Perelman School of Medicine at the University of Pennsylvania, who is also the scientific founder of Vittoria Biotherapeutics. Dr. Ruella, the senior author of the study, added, “I am honored to see our seminal study on the role of CD5 in engineered cell therapies published in Science Immunology. The study highlights the ongoing innovation and continued commitment to advance the field of cell therapy and cancer research at the University of Pennsylvania. Recognizing the transformative potential of this technology, we founded Vittoria to accelerate its translation into the clinic. The first clinical candidate developed from this research is now being evaluated in a first-in-human clinical trial at Penn Medicine as a potential new treatment for T-cell lymphoma, a disease with significant unmet therapeutic need.” The preclinical study, titled “CD5 Deletion Enhances the Anti-Tumor Activity of Adoptive T Cell Therapies,” describes the benefits of the approach of modulating the CD5 signaling pathway and utilizing a proprietary five-day manufacturing process to enhance CAR T potency, durability, and accessibility. These features may address existing challenges with current CAR T-cell treatments including CAR T exhaustion, suboptimal efficacy, and manufacturing inefficiencies. To learn more in-depth about these approaches, which underline Vittoria’s Senza5TM platform, the full publication is available here: https://www.science.org/doi/10.1126/sciimmunol.adn6509. Ruchi Patel, Ph.D., the lead author of the study and former graduate student in the Ruella laboratory at the University of Pennsylvania who recently joined Vittoria’s scientific team, added, “I am thrilled to see our work published in such a prestigious journal, and excited to contribute to the clinical translation of this groundbreaking technology in my new role at Vittoria. This brings us one step closer to enabling the next generation of transformative cell therapies and potentially improving patient outcomes.” Vittoria's VIPER-101 clinical trial is now open for enrollment for the treatment of T-cell lymphoma. Information about the trial can be found at: https://clinicaltrials.gov/study/NCT06420089?a=1. Initial clinical data is expected in early 2025 and will provide valuable insights into the Senza5 platform technology, paving the way for more effective cell therapies that can transform the treatment landscape for patients with cancer and autoimmune diseases. Editor’s Note: Ruella is the scientific founder of, a paid consultant for, and an equity holder in, Vittoria Biotherapeutics. The University of Pennsylvania holds equity in Vittoria Biotherapeutics, has received sponsored research funding from Vittoria, has licensed certain intellectual property to Vittoria and may receive future research funding and financial consideration based on development and commercialization of certain products by Vittoria. About Senza5TM Senza5TM is a proprietary cell therapy engineering and manufacturing platform that combines the power of genetic engineering and a proprietary five-day manufacturing process to maximize stemness, durability, and efficacy of its produced cell therapies by disabling the CD5 signaling pathway on engineered CAR T cells and bypassing CD5's immunosuppressive effects to amplify the therapy’s antitumor activity. The expedited five-day manufacturing process further enhances stemness, which promotes greater in vivo expansion and durability and the potential for longer-lasting responses. Senza5 can be widely utilized to improve the efficacy of engineered T-cell therapies by acting on the fundamental biology of T cells. About Vittoria Biotherapeutics Vittoria Biotherapeutics, Inc., a clinical-stage cell therapy company, is developing novel CAR T-cell therapies that transcend the limitations of current cell therapies. Based on technology exclusively licensed from the University of Pennsylvania, the Company’s proprietary Senza5TM platform unlocks the cytotoxic potential of engineered T cells and utilizes a five-day manufacturing process to maximize stemness, durability, and potency. By acting on the fundamental biology of T cells, Senza5 can be used to improve the efficacy of engineered T-cell therapies with pipeline applications in oncology and autoimmune diseases. To learn more, visit vittoriabio.com and follow us on LinkedIn. Investor Contact Vittoria Biotherapeutics, Inc. Nicholas A. Siciliano, Ph.D. Chief Executive Officer +1 215-600-1380 Media Contact LifeSci Communications Michael Tattory Associate Director LifeSci Communications +1 609-802-6265

YONGIN, South Korea, April 2, 2024 /PRNewswire/ -- GC Cell, a fully integrated cell therapy pioneer has announced poster presentations from studies of its preclinical study of GL205 (GCC2005), a CD5 CAR-NK targeting malignant T-cell lymphoma, and real-world data for the anticancer immunotherapy drug 'Immuncell-LC' at the AACR Annual Meeting 2024 that will take place in San Diego, California, on April 5-10. Continue Reading GC Cell to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024 "We are looking forward to sharing data that GL205 (GCC2005) effectively targets CD5 in malignant T-cell lymphomas, suggesting it as a new treatment option for patients with limited choices from current approved therapies. Presenting at AACR offers a significant opportunity to globally disseminate our research findings, creating anticipation for the forthcoming clinical trials of GL205 (GCC2005) slated for IND submission this year." said Sungyong Won, CSO of GC Cell. Details for the AACR 2024 abstracts are as follows: Poster Presentation Details Title: Superior anti-tumor activity of GL205, an allogeneic anti-CD5 CAR-NK for treating T-cell malignancies Authors: Miyoung Jung, Seung Min Kim, Eunsol Lee, Hyunseung Sun, Jaeyoung Yoo, Subin An, Jiyoung Park, MiAe Han, Yusun Kim, Sunglim Cho, Bokyung Min Session Title: CAR-NK, NK Engagers, and NK Modulators Session Date and Time: Monday, April 8, 2024 9:00 am PT – 12:40 pm PT Location: Poster Section 2 Poster Board Number: 7 Published Abstract Number: 1324 Title: A retrospective analysis of the clinical characteristics of metastastic solid cancer patients with cytokine-induced killer cells combined immune checkpoint inhibitor immunotherapy Lead Author: Jong Gwon Choi, Division of Oncology and Hematology, Konyang University Hospital, Daejeon, Korea Session Title: Adoptive Cellular Therapy 1 Session Date and Time: Monday, April 8, 2024 1:30 pm PT – 5:00 pm PT Location: Poster Section 39 Poster Board Number: 1 Published Abstract Number: 3595 About Immuncell-LC Immuncell-LC is the only commercially available adoptive cell therapy treatment of early-stage HCC. It is primarily composed of autologous, cultured blood-derived T lymphocytes with proven efficacy through a large-scale Phase 3 clinical trial which reduced the risk of recurrence by 37% and decreased the mortality rate by 79% compared to the control group. To date, Immuncell-LC has been administered to over 10,000 patients in South Korea without serious adverse events. About GC Cell With a core focus on cell therapy, GC Cell offers complete bio healthcare solutions from diagnosis to treatment, and the brand's comprehensive value chain spans R&D, production, commercialization, and distribution. More info: SOURCE GC Cell

PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics, a clinical-stage cell therapy company, has announced today that accomplished life sciences leader, Rosemary Mazanet, M.D., Ph.D., has joined the Company as Chief Medical Officer. Dr. Mazanet brings over 20 years of C-suite leadership experience across all stages of drug development, backed by an exceptional track record in evaluating, conceiving, articulating, and executing clinical development and strategic visions across both public and private companies. In her role, Dr. Mazanet will serve on the Company’s executive team and will be responsible for providing leadership and direction to guide Vittoria's clinical development strategy and execution, including the advancement of Vittoria’s lead candidate, VIPER-101, into the clinic for patients with T-cell lymphoma. “Drawing on her extensive expertise in the oncology and hematology drug development ecosystem, Dr. Mazanet will be an invaluable asset to Vittoria’s executive team as we enter first-in-human studies for our lead program,” said Nicholas Siciliano, Ph.D., Vittoria’s Chief Executive Officer. “Her commitment to advancing the development of novel therapeutics in oncology demonstrates her passion for improving patient outcomes, and we’re honored to have her join in our mission to deliver groundbreaking cell therapies to patients in need.” Dr. Mazanet added, “I’m thrilled to be joining the talented Vittoria team and look forward to working with our leadership and Board to progress VIPER-101 through the clinic. Vittoria’s innovative approach to CAR-T development could change the treatment paradigm for T-cell lymphoma patients struggling with this debilitating disease. I am both inspired and excited to participate in Vittoria’s mission to turn the Senza5 CD5 knockout strategy into meaningful therapies across many disease states.” Prior to joining Vittoria, Dr. Mazanet served as interim C-suite management and as a Strategic Advisor to many companies and funds through her consultancy business, R Mazanet LLC, which was established in 2004. Dr. Mazanet has experience in public equity markets having served as Managing Partner at Apelles Investment, LLC from 2007 to 2014, and as the head of Research at Oracle Partners LP beginning in 1998. Before her public equity work, Dr. Mazanet worked at Amgen, Inc., where she led Clinical Development teams that conducted successful oncology and infectious disease programs resulting in multiple product approvals. Dr. Mazanet is an Emeritus Trustee at the University of Pennsylvania Health System and has served as the Chair of the Executive Advisory Board for the Wharton Leonard Davis Institute since December 2020. Dr. Mazanet holds a B.A. in biology from the University of Virginia, and an M.D. and Ph.D. from the University of Pennsylvania. Dr. Mazanet received her clinical training in internal medicine and oncology at Harvard Hospitals. About Senza5 Senza5 is a proprietary cell therapy engineering and manufacturing platform that combines the power of genetic engineering and a proprietary five-day manufacturing process to maximize stemness, durability, and efficacy of its produced cell therapies by disabling the CD5 signaling pathway on engineered CAR-T cells, and bypassing CD5's immunosuppressive effects to amplify the therapy’s antitumor activity. Stemness is further enhanced by the expedited five-day manufacturing process which promotes greater in vivo expansion and durability, and the potential for longer-lasting responses. By acting on the fundamental biology of T cells, Senza5 can be widely utilized to improve the efficacy of engineered T-cell therapies. About VIPER-101 VIPER-101 is a gene-edited, autologous, CAR-T cell therapy for the treatment of patients with relapsed or refractory T-cell lymphoma. Viper-101 is uniquely engineered by Vittoria’s proprietary Senza5 technology, to both avoid fratricide and unlock the benefit of circumventing the inhibitory CD5 signaling pathway. Vittoria is currently enrolling in its Phase 1 study of VIPER-101 and anticipates announcing data from this trial in the first half of 2025. About Vittoria Biotherapeutics Vittoria Biotherapeutics, Inc., is developing novel CAR-T cell therapies that transcend the limitations of current cell therapies. Based on technology exclusively licensed from the University of Pennsylvania, the Company’s proprietary Senza5 platform unlocks the antitumor potential of engineered T cells and utilizes a five-day manufacturing process to maximize stemness, durability, and target cell cytotoxicity. By acting on the fundamental biology of T cells, Senza5 can be used to improve the efficacy of engineered T cell therapies with pipeline applications in oncology and autoimmune diseases. To learn more, visit vittoriabio.com and follow us on LinkedIn. Investor Contact Vittoria Biotherapeutics Nicholas A. Siciliano, Ph.D. Chief Executive Officer +1 215-600-1380 Media Contact LifeSci Communications Jason Braco, Ph.D. jbraco@lifescicomms.com +1 646-876-4932